Skip to main content

Biotechnology

Biotechnology drives breakthroughs in medicine, agriculture, and manufacturing. The National Academies assess advances, risks, and regulations that shape responsible innovation in the life sciences. 

What's happening

Inaugural Cohort of Biotechnology Regulatory Fellows Present Capstone Projects

Feature Story

The 10 inaugural fellows of the National Academies’ Biotechnology Regulatory Fellowship Program recently completed their six-month residency in Washington, D.C. The fellowship was developed to help early-career professionals build an understanding of the evidence base needed to meet potential regulatory challenges presented by novel products of biotechnology.

Aug 19, 2026
Inaugural Biotechnology Regulatory Fellowship capstone project event 2026

The Risks and Benefits of Synthetic Cells: Q&A with Peter Carr

Feature Story

In an interview, synthetic biologist Peter Carr explains research on synthetic cells, their potential benefits and hazards, and how governance of this research should work. Carr co-chaired a recent National Academies study of the subject.

Jul 7, 2026

Does the current Ebola vaccine protect against every type of Ebola virus?

Based on Science

No. The currently approved Ebola vaccine used for outbreak response is called Ervebo. Ervebo protects against one species of Ebola virus, called Zaire ebolavirus. It has not been proven to protect against other Ebola viruses, including Bundibugyo virus. The 2026 outbreak in Uganda and the Democratic Republic of the Congo is caused by Bundibugyo virus, a different Ebola virus for which there is currently no approved vaccine.

May 22, 2026
A doctor in Africa checks the vaccine syringe
Subscribe to Emails from the National Academies
Stay up to date on activities, publications, and events by subscribing to email updates.